Imunotherapy in clinical practice: Real world multicentric Brazilian experience
Juliano Cé Coelho, A. Gelatti, Carolina Dutra, T. Rebelato et autres
Background: Immunotherapy is a new standard of care for metastatic NSCLC patients. Approval of this therapy was based on randomized phase 3 trials. Clinical trials employees’ strict patient selection criteria, and this may not represent the ‘real-world’ population.
br (code pays fourni par la source)